Biotechnology

Affinity discovers potent SARS-CoV-2 antibodies

MELBOURNE, Australia, July 2, 2020 /PRNewswire/ -- Melbourne-based Affinity Biosciences Pty Ltd (Affinity), a privately held company focused on antibody discovery for cancer therapeutics, today announces the discovery of potent antibodies with therapeutic potential against COVID-19. In March, Af...

2020-07-02 12:25 555

Thermo Fisher Scientific Launches New MAS Omni Infectious Disease Quality Controls

FREMONT, California, July 1, 2020 /PRNewswire/ -- Thermo Fisher Scientific, the world leader in serving science, today announced the availability of the Thermo Scientific MAS Omni Infectious Disease quality control sets for monitoring serological assays for analytes such as HIV 1&2, Hepatitis B &...

2020-07-01 20:00 522

Mentice Appoints Thanos Karras as Americas General Manager to Accelerate Group's Growth Strategy

GOTHENBURG, Sweden, July 1, 2020 /PRNewswire/ -- Mentice AB (STO: MNTC) today announced the appointment ofThanos Karras as the company's new General Manager for Americas. Thanos' appointment will play a critical role in supporting Mentice's continual growth strategy and will help accelerate its l...

2020-07-01 16:52 501

RhoVac Marketed in International Press

STOCKHOLM, July 1, 2020 /PRNewswire/ -- RhoVac AB ("RhoVac") is marketed in the latest edition of the international trade press outlet, MedNous, through a written commentary by CEOAnders Månsson. In order to further attract the attention of potential partners and increase their interest in Rh...

2020-07-01 15:49 496

FDA Approves BAVENCIO as First-Line Maintenance Treatment for Patients with Locally Advanced or Metastatic Urothelial Carcinoma

DARMSTADT, Germany and NEW YORK, July 1, 2020 /PRNewswire/ -- Merck and Pfizer Inc. (NYSE: PFE) today announced that the US Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for BAVENCIO® (avelumab) for the maintenance treatment of patients with...

2020-07-01 07:30 2914

Janssen Korea Ltd. and Johnson & Johnson Innovation Announce Launch of Seoul Innovation QuickFire Challenge for Healthcare in the New Normal in Collaboration with Seoul Metropolitan Government and Korea Health Industry Development Institute

- QuickFire Challenge calls on innovators to identify and accelerate potential solutions aiming to improve patient care in our post-COVID world. - Awardees will receive up to KRW150,000,000 (approximately US $125,000)[1], residence at the Seoul Bio Hub, and mentorship and coaching from experts at...

2020-07-01 05:30 710

AGC Biologics Expands Development Capacities for pDNA Services at Heidelberg Site

Expansion will help meet the growing demand for plasmid DNA offerings SEATTLE, June 30, 2020 /PRNewswire/ -- Committed to continuous innovation and expansion of its service offerings, AGC Biologics has announced the expansion of its pDNA Center of Excellence in Heidelberg, Germany. The global bi...

2020-06-30 21:00 540

Ajinomoto Bio-Pharma Services Introduces AJILITY Fast Track Platform for Drug Product Manufacturing

SAN DIEGO, June 30, 2020 /PRNewswire/ -- Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a leading provider of biopharmaceutical contract development and manufacturing services, is pleased to announce the launch of AJILITY™, a flexible and agile drug product manufacturing platform, designed to ...

2020-06-30 20:10 442

Thrombosis Research Institute (TRI) Announce ETHIC Trial to Evaluate the Potential Benefits of Early Administration of LMWH in Patients with COVID-19

- Clinical trial will recruit approximately 1400 patients in 10 countries starting in July  - Participants will be randomised to receive the low molecular weight Heparin enoxaparin or current standard of care for up to 3 weeks from the time of diagnosis  - The study is supported through an inve...

2020-06-30 14:00 453

AOBiome Reports Successful Clinical Trials (Phase 2a in Adults and Phase 1b in Pediatrics) in Pruritus (Itch) Associated with Atopic Dermatitis: Initiates Phase 2b Clinical Trial in Adults

AOBiome's 576 patient Phase 2b trial commences patient enrollment CAMBRIDGE, Massachusetts, June 30, 2020 /PRNewswire/ -- AOBiome Therapeutics, Inc. ("AOBiome"), a leading clinical-stage microbiome company focusing on inflammation,  announced initiation of a Phase2b clinical trial in pruritus (i...

2020-06-30 13:00 414

MedAlliance Gains CE Mark Approval for Coronary SELUTION SLR™ Sirolimus Drug Eluting Balloon

NYON, Switzerland, June 30, 2020 /PRNewswire/ -- MedAlliance has announced the award of its second CE Mark: SELUTION SLR™ 014 PTCA, a novel Sirolimus Drug Eluting Balloon (DEB), for the treatment of coronary arterial disease. This includes indications for both de-novo lesions as well as in-stent ...

2020-06-30 08:00 479

Global Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2020

Added 18,488 New Subscribers in 4Q20 4Q20 Revenues Increased by 19.2% YoY to RMB299.9 Million ($42.4 Million) 4Q20 Operating Income Increased by 68.1% YoY to RMB149.3 Million ($21.1 Million) Non-GAAP Operating Income Up 58.7% YoY to RMB161.7 Million ($22.8 Million) Conference Call to be Held on Jun...

2020-06-30 04:16 4468

RevImmune Announces Phase II Trial of the T-Cell Growth Factor CYT107 for COVID-19

Under Way in Europe Since May, In Preparation in the U.S.  Designated As An Urgent Public Health National Priority In U.K. BETHESDA, Maryland, June 29, 2020 /PRNewswire/ -- RevImmune, a privately held biotechnology company developing CYT107 immune therapy for infectious diseases and cancer, an...

2020-06-29 21:00 538

Picosun's Medical ALD Solutions Ensure Excellent Hermetic Encapsulation

ESPOO, Finland, June 29, 2020 /PRNewswire/ -- Picosun Group reports excellent results in ALD-organic bilayer encapsulation of metal electrodes for neuroprosthetics and bioelectronic medicine. Group also reports superior hermetic barrier performance of its ALD nanolaminates against corrosive ion ...

2020-06-29 11:34 523

Philogen Received Clinical Trial Authorisation With Nidlegy in Nonmelanoma Skin Cancer

SIENA, Italy, June 26, 2020 /PRNewswire/ -- Philogen S.p.A., a privately-owned biotechnology company, is pleased to announce that the Swiss national competent authority Swissmedic issued the authorization to run a clinical phase II study in patients with locally advanced, not metastatic nonmelano...

2020-06-26 15:00 820

ERBA Mannheim Launches CE Marked COVID-19 IgM Antibody ELISA

LONDON, June 25, 2020 /PRNewswire/ -- In response to the ongoing COVID-19 pandemic,Erba Mannheim today launched the ErbaLisa COVID-19 IgM ELISA kit for detection of IgM antibodies to SARS-CoV-2. IgM antibodies are produced first and detectable during disease onset, so using the new assay in comb...

2020-06-25 01:08 1062

Global Cord Blood Corporation to Report Fourth Quarter and Full Year Fiscal 2020 Financial Results

HONG KONG, June 24, 2020 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) (the "Company"),China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced that it plans to release financial results fo...

2020-06-24 19:30 10316

Philogen Received Combination Pack Approval for Nidlegy

SIENA, Italy, June 24, 2020 /PRNewswire/ -- Philogen S.p.A., a privately-owned biotechnology company, is pleased to announce that, onJan. 30, 2020, EMA's CHMP expressed a favorable opinion to the request of a combination pack for the to-be-marketed pharmaceutical form of NidlegyTM, a combination ...

2020-06-24 15:00 556

Akeso Appoints Prof. Bradley Monk as Lead Gynecologic Oncology Advisor and Chair of the Steering Committee

LOS ANGELES, June 24, 2020 /PRNewswire/ -- Akeso, Inc. ("Akeso", 9926.HK) announced the appointment of ProfessorBradley J. Monk, MD, FACOG[1], FACS[2] as Lead Gynecologic Oncology Advisor and Chair of the Steering Committee for its global Phase 2, multicentre registration study to evaluate the ef...

2020-06-24 12:55 5462

InxMed Released Research Data of "FAK inhibitor IN10018 overcomes drug resistance of KRAS G12C inhibition" at 2020 AACR Annual Meeting

SHANGHAI, June 24, 2020 /PRNewswire/ -- InxMed (Shanghai) Co., Ltd. ("InxMed" or "Company"), a clinical stage biotech company dedicated to developing innovative, individualized medicines with international impact, announced that the company has released the research data of "FAK inhibitor IN10018...

2020-06-24 08:41 285
12345 ... 65